University of Victoria: CHEM 212 Course

A scene of students attentively sitting in a lecture room at a university from behind
Events

University of Victoria: CHEM 212 Course

When:
Time:

On October 16, 2024, Nick Allan, Bio Services Manager at StarFish Medical, delivered a lecture titled “Analytical Chemistry and Medical Device Design” to the CHEM 212 course at the University of Victoria. This session explored the pivotal role analytical chemistry plays in developing innovative medical devices.

Nick Allan, a microbiologist and serial entrepreneur, shared his extensive experience in biofilm research, material selection, and the application of analytical methods to ensure the functionality and compliance of medical devices. The CHEM 212 course lecture featured real-world case studies, including:

  • Case Study I: Using analytical chemistry to validate medical device performance.
  • Case Study II: Developing a kinetic fluorescence assay for real-time analytics.

Key topics discussed in the CHEM 212 course lecture included:

  • Regulatory Considerations: Emphasizing the importance of robust analytical methods for meeting regulatory standards.
  • The Role of Analytical Chemistry: Highlighting its critical role in material selection, formulation, and testing during medical device development.
  • High-Pressure Liquid Chromatography (HPLC): Showcasing its application in the development and validation of device components.

For students, this lecture provided valuable insights into integrating analytical techniques with biotechnology and medical device innovation.

Presenter Bios:

Headshot of Nick Allan.

Nick Allan

Bio Services Manager
StarFish Medical

Nick has over 19 years of regulatory and product development experience in the field of microbiology and assay development. Over his career, Nick has provided innovative solutions to issues ranging from proof-of-concept studies for rapid detection point of care assays, to full scale regulatory submission studies. At StarFish Medical, he applies this skill set to product development and currently manages the Bio Services division, formed in 2015 to support novel infectious disease detection platforms and gene and cell therapy products. Through the Bio Services department, Nick oversees advanced equipment, BSL2 facilities and personnel with advanced degrees and training in Bio Services focus areas.